FDA Delays Decision on Alexza Antipsychotic Treatment

Law360, New York (January 23, 2012, 6:47 PM EST) -- The U.S. Food and Drug Administration moved its decision date back by three months on Alexza Pharmaceuticals Inc.'s schizophrenia drug delivery system, citing the company's recent update to its new drug application, Alexza announced Monday.

The Mountain View, Calif.-based company had submitted a new Risk Evaluation and Mitigation Strategy program for its Adasuve treatment to the FDA on Jan. 10, which the agency considered a major amendment to the NDA, worthy of an extra three months to review the application, Alexza said in a statement....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.